Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Researchers use patient's own stem cells to correct genetic alteration that causes SCD

Using a patient's own stem cells, researchers at Johns Hopkins have corrected the genetic alteration that causes sickle cell disease (SCD), a painful, disabling inherited blood disorder that affects mostly African-Americans. The corrected stem cells were coaxed into immature red blood cells in a test tube that then turned on a normal version of the gene.

29 Sep 2011

YM BioSciences begins enrollment in CYT387 Phase II trial for myelofibrosis

YM BioSciences Inc. today announced that it has enrolled the first patients in its multi-center Phase II trial of CYT387 administered twice-daily (BID) for the treatment of myelofibrosis.

28 Sep 2011

Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer-related products, today announced that data from several clinical trials of nimotuzumab are scheduled be reported at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.

27 Sep 2011

Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced long-term results of the Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia.

26 Sep 2011

Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has achieved the target enrollment of the minimum of 100 evaluable relapsed or refractory peripheral T-cell lymphoma (PTCL) patients in the BELIEF registration trial.

26 Sep 2011

Percutaneous hepatic perfusion extends survival time for melanoma patients

Melanoma of the eye frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients live for a year. Now, final results from a phase III study have demonstrated that a new treatment significantly extends the time patients can live without the disease progressing.

26 Sep 2011

Study identifies areas for cancer care cost and quality improvements

With cancer care costs rising at an unprecedented rate, The US Oncology Network, one of the nation's largest networks of community-based oncologists dedicated to advancing cancer care in America, reported a study that identified areas where both the cost and quality of care could be improved.

26 Sep 2011

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Patrys Limited has announced that its lead anti-cancer antibody PAT-SM6 has shown significant activity in preclinical studies of multiple myeloma.

26 Sep 2011

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

The U.S. Food and Drug Administration today approved Soliris (eculizumab) to treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a rare and chronic blood disease that can lead to kidney (renal) failure and is also associated with increased risk of death and stroke.

26 Sep 2011

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of promising hematology and cancer-related products, today reported operational and financial results for its 2011 fiscal year, ended June 30, 2011.

23 Sep 2011

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

Acetylon Pharmaceuticals today announced the initiation of patient treatments in a three-part Phase 1-2a clinical trial of ACY-1215, an oral Class II histone deacetylase (HDAC) inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

22 Sep 2011

John Theurer Cancer Center to join MMRF's Personalized Medicine Initiative

The John Theurer Cancer Center at Hackensack University Medical Center, a top 50 U.S. News best hospital for cancer, is one of the first four clinical sites enrolling patients in a landmark study designed to uncover the molecular segments and variations of multiple myeloma.

22 Sep 2011

Study confirms biphasic nature of alcohol's effect on progression of atherosclerosis

An excellent study among experimental mice has reported very dramatic differences between the effects of alcohol administered in moderation on a daily basis and the same total weekly amount of alcohol administered on only two days of the week: (replicating binge drinking).

21 Sep 2011

Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that top-line data from part one of a two-part Phase 1 study of SPI-1620 in combination with docetaxel was presented in an oral presentation at the 12th International Conference on Endothelin, held in Cambridge, United Kingdom, from September 11-14, 2011. Part one of the study has been completed, while part two is ongoing.

19 Sep 2011

CWRU receives NCI grant to advance treatment of gastrointestinal cancers

The National Cancer Institute has awarded $11.3 million to Case Western Reserve University School of Medicine to establish a center of excellence for research on gastrointestinal cancers.

19 Sep 2011

Case Western Reserve awarded $11.3M to establish gastrointestinal cancer research center

The National Cancer Institute has awarded $11.3 million to Case Western Reserve University School of Medicine to establish a center of excellence for research on gastrointestinal cancers. The funding designates the university as a Specialized Program of Research Excellence (SPORE) in Gastrointestinal (GI) Cancers - recognition extended to just one institution this year.

17 Sep 2011

Simple strategies prevent bloodstream infections and save hundreds of patient lives

Following some basic rules of central line hygiene and maintenance, Johns Hopkins Children's Center and 87 other pediatric hospitals have, over five years, saved hundreds of patient lives and more than $100 million by preventing nearly 3,000 central line bloodstream infections, hospital officials announced on Monday, Sept. 12.

16 Sep 2011

Leica Microsystems bringing digital pathology excellence to the hematopathology workshop

Leica Microsystems, world-leading providers of Total Digital Pathology solutions, are a proud platinum sponsor of this year’s joint workshop of the Society for Hematopathology and the European Association for Haematopathology (SH/EAHP) being held at the Ritz-Carlton Marina Del Rey, Los Angeles, USA, from October 27-29, 2011.

15 Sep 2011

Hengrui, Shanghai ChemPartner enter strategic development partnership for monoclonal antibodies

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Jiangsu Hengrui Medicine Co., Ltd., a leading Chinese pharmaceutical company, today announced that Shanghai ChemPartner, a wholly owned subsidiary of ShangPharma, and Hengrui have entered into a strategic partnership for the development of novel therapeutic monoclonal antibodies.

15 Sep 2011

Celecoxib inhibits GSK3 enzyme in lung cancer cells

Several clinical studies have shown that taking the anti-inflammatory drug celecoxib can reduce the risk of developing polyps that lead to colon cancers, at the cost of increasing the risk of heart disease. But what if this tradeoff was not necessary?

14 Sep 2011

Hematology News and Research

Further Reading

Researchers use patient's own stem cells to correct genetic alteration that causes SCD

YM BioSciences begins enrollment in CYT387 Phase II trial for myelofibrosis

Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011

Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL

Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL

Percutaneous hepatic perfusion extends survival time for melanoma patients

Study identifies areas for cancer care cost and quality improvements

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

John Theurer Cancer Center to join MMRF's Personalized Medicine Initiative

Study confirms biphasic nature of alcohol's effect on progression of atherosclerosis

Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma

CWRU receives NCI grant to advance treatment of gastrointestinal cancers

Case Western Reserve awarded $11.3M to establish gastrointestinal cancer research center

Simple strategies prevent bloodstream infections and save hundreds of patient lives

Leica Microsystems bringing digital pathology excellence to the hematopathology workshop

Hengrui, Shanghai ChemPartner enter strategic development partnership for monoclonal antibodies

Celecoxib inhibits GSK3 enzyme in lung cancer cells

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo